These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 32897581)

  • 21. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB;
    JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 25. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
    BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
    Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
    J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of P2Y
    Thomas CD; Williams AK; Lee CR; Cavallari LH
    Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.
    Soh BWT; Cusack R; Waters M; O'Connor C; Arnous S; Kiernan T
    Br J Clin Pharmacol; 2023 Aug; 89(8):2413-2422. PubMed ID: 36890711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y
    JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
    Cavallari LH; Franchi F; Rollini F; Been L; Rivas A; Agarwal M; Smith DM; Newsom K; Gong Y; Elsey AR; Starostik P; Johnson JA; Angiolillo DJ
    J Transl Med; 2018 Apr; 16(1):92. PubMed ID: 29642909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
    Klein MD; Williams AK; Lee CR; Stouffer GA
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
    Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
    JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.